Polish Journal of Pathology

Abstract

2/2025 vol. 76
Case report

Multifocal cutaneous leishmaniasis in a patient treated with golimumab for psoriaticarthritis

Veronica Forte 1
,
Anna Silvia Biamonte 2
,
Massimo Menichini 3
,
Fabrizio Liberati 4
,
Luca Ventura 1
  1. Division of Pathology, San Salvatore Hospital, L’Aquila, Italy
  2. Dermatology Unit, Primary Health Care District, L’Aquila, Italy
  3. Division of Nuclear Medicine, San Salvatore Hospital, L’Aquila, Italy
  4. Division of Pathology, San Camillo de’ Lellis Hospital, Italy
Pol JPathol 2025; 76 (2): 158-162
DOI: https://doi.org/10.5114/pjp.2025.153977
Online publish date: 2025/09/22
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
Leishmaniasis is a zoonosis caused by protozoans transmitted by sandflies. Immu­nosuppression is a risk factor for developing leishmaniasis in patients treated with TNF inhibitors for autoimmune diseases. A 65-year-old man with a 14-year histo­ry of psoriatic arthritis in treatment with methotrexate, treated with golimumab during the last 2.5 years, presented ulcerations of the buttocks and upper back. Histopathological findings allowed us to yield the diagnosis of cutaneous leishman­iasis. Therapy was suspended and the patient underwent appropriate treatment. Five cases of leishmaniasis in patients treated with golimumab were reported in literature and ten cases were mentioned in retrospective reviews.

Keywords

Leishmania, psoriasis, psoriatic arthritis, golimumab performance

Share
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications